Precision Platform Study of Refractory Triple-negative Breast Cancer Based on Molecular Subtyping（(A Phase II, Open-label, Single-center Platform Study）

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05749588

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:29:09.469116+00:00

Published At

2026-04-16T00:00:00+00:00

Record Updated At

2026-04-16

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Triple-negative Breast Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-04-16"

protocolSection.identificationModule.nctId

"NCT05749588"

protocolSection.identificationModule.officialTitle

"Precision Platform Study of Refractory Triple-negative Breast Cancer Based on Molecular Subtyping\uff08(A Phase II, Open-label, Single-center Platform Study\uff09"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Triple-negative Breast Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.